Table 2.
Demographic and clinical characteristics of patients with frail phenotype compared to patients with fit phenotype at the end of the study (T1). CD: Crohn’s disease; UC: ulcerative colitis; BMI: body mass index; EIMs: extraintestinal manifestations; ISS: immunosuppressors.
| Characteristics at T1 | Frail Phenotype (N = 11) |
Fit Phenotype (N = 12) |
p-Value |
|---|---|---|---|
| Age (years), median [range] | 59 [27–78] | 57.5 [24–71] | 0.67 |
| Female gender, n (%) | 8 (73) | 8 (67) | >0.99 |
| CD, n (%) | 6 (55) | 5 (42) | 0.68 |
| UC, n (%) | 5 (45) | 7 (58) | 0.67 |
| Duration of disease (months), median [range] | 180 [24–492] | 168 [36–432] | 0.88 |
| BMI (kg/m2), median [range] | 25 [18–31] | 24 [16–33] | 0.78 |
| History of EIMs, n (%) | 7 (64) | 3 (25) | 0.10 |
| History of steroid dependence/resistance, n (%) | 4 (36) | 6 (50) | 0.68 |
| Clinically active disease, n (%) | 8 (73) | 2 (17) | 0.012 |
| Current therapy with steroids, n (%) | 0 (0) | 1 (8) | >0.99 |
| Current therapy with biologic agents, n (%) | 3 (27) | 9 (75) | 0.039 |
| Current therapy with ISS, n (%) | 0 | 0 | - |
| Current therapy with mesalamine, n (%) | 7 (64) | 11 (92) | 0.15 |
| Charlson comorbidity index, median [range] | 3 [0–5] | 1.5 [0–4] | 0.31 |
| Psychiatric diseases, n (%) | 2 (18) | 1 (8) | 0.59 |
| Heart failure, n (%) | 0 | 0 | - |
| Pneumological diseases, n (%) | 1 (9) | 0 | 0.48 |
| Neurodegenerative diseases, n (%) | 0 | 1 (8) | >0.99 |
| Post-COVID fatigue, n (%) | 1 (9) | 1 (8) | >0.99 |